DEFINITIVE CONTRACT
Active75N93026C00013
Department of Health and Human Services › National Institutes of Health › NATIONAL INSTITUTES OF HEALTH NIAID
$1.9M
obligated · signed 2 months ago
TO CONDUCT INVESTIGATIONAL NEW DRUG (IND)-ENABLING STUDIES OF A PRE-CLINICAL CANDIDATE FOR THE TREATMENT OF NEUROTROPIC ALPHAVIRUSES.
Performance timeline
Start
Aug 3, 2026
End
Jul 31, 2028
with all options
Loading status
Estimated start: Jul 31, 2027
UNIVERSITY OF TENNESSEE
Contract 75N93026C00013
UEI
X1M1PN3KG3E7
Parent Company
UNIVERSITY OF TENNESSEE
Capabilities & Certifications
Headquarters Location
Congressional District: 09
Current Obligation
$1,851,661
Base + Exercised Options
$1,851,661
Total Ceiling Value
$9,349,598
Contract Type
COST NO FEE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Place of Performance
Congressional District: 09
Awarding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH NIAID
Office
Funding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH NIAID
Office
Solicitation procedures, competition exceptions, labor standards and account totals.